Last $20.92 USD
Change Today +0.76 / 3.77%
Volume 68.8K
OMED On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Paul J. Hastings

Chairman, Chief Executive Officer and President, OncoMed Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 244 board members in 9 different organizations across 11 different industries.

See Board Relationships
54$2,499,846
As of Fiscal Year 2013

Background*

Mr. Paul J. Hastings has been the Chief Executive Officer and President at OncoMed Pharmaceuticals, Inc. since January 2006 and has been its Chairman since August 2013. Mr. Hastings served as a Business Advisor at Valocor Therapeutics, Inc. He joined OncoMed in 2006. He has over 20 years of experience as a biotechnology and pharmaceutical industry executive. He served as the President and Chief Executive Officer of QLT Inc. from February 2002 to September 2005, where ...

Read Full Background

Corporate Headquarters*

800 Chesapeake Drive
Redwood City, California 94063

United States

Phone: 650-995-8200
Fax: 650-995-8600

Board Members Memberships*

Chief Executive Officer, President, and Director
Director
Director
Director
Chairman
Chairman
Former Director
1998-N/A
Former Chief Executive Officer, President and Director
2000-Present
Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
2002-2005
Former Chief Executive Officer, President and Director
2006-Present
Chairman, Chief Executive Officer and President
2010-Present
Director
2011-Present
Lead Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
2012-Present
Director, Member of Audit Committee and Member of Compensation Committee

Education*

BS
University Of Rhode Island

Other Affiliations*

Annual Compensation*

Salary$453,604
Bonus$175,000
Total Annual Compensation$628,604

Stock Options*

Exercisable Options509,059
Unexercisable Options143,334
Total Number of Options652,393

Total Compensation*

Total Annual Cash Compensation$791,902
Total Short Term Compensation$628,604
Total Calculated Compensation$2,499,846
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMED:US $20.92 USD +0.76

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOMED PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.